ARROWHEAD PHARMACEUTICALS, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.74 per share for the 12-month period ending 2011-09-30, per its 10-K filed 2012-12-28.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2012-12-28
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-06-30 was -$0.01.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2011-03-31 was $0.53.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2010-06-30 was -$0.01.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2011 was $0.74.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2010 was -$0.41.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month as first filed | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|---|
| 2011-09-30 | $0.74 10-K · filed 2012-12-28 | ||||
| 2011-06-30 | -$0.01 10-Q · filed 2012-08-13 | $0.74 10-Q · filed 2012-08-13 | $0.07 10-Q · filed 2011-08-08 | ||
| 2011-03-31 | $0.53 10-Q · filed 2012-05-08 | $0.75 10-Q · filed 2012-05-08 | |||
| 2010-09-30 | -$0.41 10-K · filed 2011-12-20 | ||||
| 2010-06-30 | -$0.01 10-Q · filed 2011-08-08 | -$0.03 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |